home > ebr

European Biopharmaceutical Review


European Biopharmaceutical Review (EBR) is a journal designed to fill a unique position in scientific publishing. Published quarterly, it provides a dedicated platform of communication and information for the European biopharmaceutical market across Europe, North America & the rest of the world.

With editorial consisting of in-depth articles, case studies, meeting and report reviews written by specialists with hands-on experience in the biopharmaceutical industry, traditional multi-national pharmaceutical companies, investment houses and industry-associated governmental, economic and societal bodies. Each quarterly edition examines topical areas of importance across the board of biopharmaceutical research and development, with regular feature sections on BioBusiness Development, Research and Innovation, BioDiscovery, BioManufacturing plus special focuses on geographic or therapeutic territories.

For further information please contact:


Jennifer Sadler-Venis


David Hirsh   



Connect with us on Twitter: follow @EBRmagazine

Read our publications on the go in the Samedan app for iPhone and iPad. You can download issues for offline reading and our archives go as far back as 2008! Download for free on the App Store.

View the
digital version
of EBR

Featured in this issue
Editors Letter
Editor’s Letter

Dr Deborah O’Neil, Editor of EBR, highlights the connections and debates that interlink the articles by our contributors this issue, with a particular focus on the protein problem and the need for tighter regulation across fields such as biomarkers and personalised medicine.
Cells and Serums

Culture Clash

Jessie HT Ni at Irvine Scientific explores the latest developments in the world of serums. With their benefits and risks well known, we are beginning to further understand their effects on phenotypes and, as a result, our knowledge of cell biology is expanding.
Biomarkers and Personalised Medicine

Essential Tools

Dr Mélanie Bodnar-Wachtel and Dr Tanja Schubert at Bioclinica Lab reveal how biomarkers are being used in the treatment of Alzheimer’s disease and cancer. As they become essential, they are revolutionising the manufacture of advanced therapies and allowing for new and innovative practices and partnership.

Edited by
Dr Deborah O'Neil,
Chief Executive and Scientific Officer,
NovaBiotics Ltd
Published quarterly in
January, April,
July and October


Industry Events

11th Pharmaceutical Logistics

18-19 May 2017, Copthorne Tara Hotel, London, UK

As outsourcing logistical tasks continues to be an emerging lucrative trend within the pharma industry, SMi Group proudly announces the return of its 11th annual Pharmaceutical Logistics event to London on 18-19th May 2017. Registration is now live on
More info >>

News and Press Releases

Healthera Launches Digital Health Management Platform

Digital health management company announces the launch of its Health Management App
More info >>

air transport logo


White Papers

PhlexEview: Transforming Costly Paper Processes into Value Driven Compliance

Phlexglobal Ltd

Looking at some of the challenges of traditional paper-based Trial Master Files (TMFs), and how they can be overcome with Phlexglobal's best in breed electronic TMF system, PhlexEview.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement